Let's Talk
Let’s Talk

Author: gaurav

“Live from the Lab” at Sapient: On-Demand Virtual Lab Tour with Bruker

Watch the Livestream Recording | Presented by Bruker Watch the full recording of our recent lab tour showing how Sapient’s next-generation, ultra-high throughput rapid liquid chromatography-mass spectrometry (rLC-MS) platform leverages the unique bioanalytical capabilities of the Bruker timsTOF Pro 2 to enable large-scale biomarker profiling. See how the systems perform nontargeted measurement of >15,000 circulating small molecule biomarkers per… Continue reading “Live from the Lab” at Sapient: On-Demand Virtual Lab Tour with Bruker

Nature Webinar | Beyond the genome: small-molecule biomarkers drive new advances in drug discovery

Now On Demand | Hosted by Nature Research Watch Now Human disease is a highly dynamic process. While next-generation genomic sequencing has provided enormous insight into the genetic underpinnings of human health and disease, dynamic measures that integrate changes in human pathobiology are still lacking in therapeutic development, as are measures of the influence of external factors… Continue reading Nature Webinar | Beyond the genome: small-molecule biomarkers drive new advances in drug discovery

Discovery of an Early Diagnostic Biomarker for NASH

The incidence and prevalence of nonalcoholic fatty liver disease (NAFLD) continue to rise worldwide, estimated to affect over one-quarter of the global adult population today. A portion of NAFLD patients will progress to develop nonalcoholic steatohepatitis (NASH), which can cause liver inflammation and cirrhosis, but the mechanisms underlying NAFLD progression to NASH are still not… Continue reading Discovery of an Early Diagnostic Biomarker for NASH

VibeCast Podcast: Are Biomarkers the Future?

“Diagnostics have evolved tremendously. You could argue that the greatest benefit in human survival has come over the last 50 years because we’ve gotten much better at diagnosing disease at an earlier stage. But there’s still quite a ways to go before we’re perfect in this. One of the real ways we can advance further… Continue reading VibeCast Podcast: Are Biomarkers the Future?

How metabolomics can enrich preclinical safety studies

Preclinical safety assessments play a pivotal role in mitigating risk to enhance drug development success. Early identification of toxicological effects associated with new drug candidates can help prevent unnecessary costs, time, and resources spent on unsafe compounds or allow adjustments to where the drug no longer produces observable adverse effects, supporting its safe advancement into… Continue reading How metabolomics can enrich preclinical safety studies

“Beyond Biotech” Podcast: A look at metabolite biomarkers with Sapient

“My hope is that in the very near future, in the next decade, an individual would go to a doctor’s office once a year and instead of measuring 12 things in a blood sample, we are going to measure several hundred things in that blood sample, and we are going to know exactly the information… Continue reading “Beyond Biotech” Podcast: A look at metabolite biomarkers with Sapient

Biocom LifeLines Magazine Feature: “Illuminating unknowns in the dynamic interplay of genetics, environment, and disease”

Biocom California recently asked Sapient to contribute an article for its Lifelines Magazine, a forum sharing insights and innovations that are leading the way for life science. We discuss why discovery of dynamic, non-genetic biomarkers is needed to elucidate still-unknown contributors and causes of disease, and take a closer look at the technologies and approaches that are… Continue reading Biocom LifeLines Magazine Feature: “Illuminating unknowns in the dynamic interplay of genetics, environment, and disease”

Experts On… Biomarker Translation of Discoveries in Blood to Other Matrices

Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those insights with you. While blood is a rich resource for small molecule biomarker discovery, Sapient’s approaches can be leveraged across diverse sample types including tissue, urine, CSF, tears, aqueous humor, and other matrices. Sapient’s Head… Continue reading Experts On… Biomarker Translation of Discoveries in Blood to Other Matrices

Small Molecule Biomarkers + Adaptive Clinical Trials: Optimize Dosing & Timing of Treatments

Adaptive clinical trial designs are an emerging approach that bring flexibility to traditional linear study designs by adding a “review, adapt” loop that allows adjustments to be made during the course of the trial if warranted. Adaptive designs can be particularly helpful to optimize dosing and timing of treatment in trials, and this is where… Continue reading Small Molecule Biomarkers + Adaptive Clinical Trials: Optimize Dosing & Timing of Treatments

Experts On… Translating Biomarker Discoveries into Real-World Assays

Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those insights with you. The translation of small molecule biomarker discoveries into clinical assays for real-world use is critical to ensure important measures of biological processes, disease progression, and drug response can be made actionable in… Continue reading Experts On… Translating Biomarker Discoveries into Real-World Assays

Let's Talk